Work

Primary advanced malignant melanoma of the uterine cervix treated with a combination of nivolumab and concurrent radiotherapy: A case report

Year: 2025

Type: article

Abstract: • Cervical malignant melanoma is very rare and has no standard treatment • Nivolumab plus radiotherapy was used as the initial treatment in this case • Tumor shrinkage and symptom control were achieved with combination therapy • The patient developed lymph node metastasis and died 16 months after treatment • This is the first report on use of nivolumab and radiotherapy for cervical melanoma Malignant melanoma accounts for 1–4% of all gynecological malignancies, with most cases originating in the vulva and/or vagina. Primary malignant uterine melanomas are rare. Although there are reports of initial treatment with nivolumab and combination therapy with nivolumab and radiotherapy for recurrent lesions, no standardized treatment protocol has been established. This case report describes a 74-year-old woman diagnosed with International Federation of Gynecology and Obstetrics stage IV primary malignant melanoma of the cervix. Nivolumab and radiotherapy were concurrently administered to the primary lesion, resulting in tumor mass reduction. However, new pelvic lymph node metastases were observed at 6 months. The same combination therapy was administered but proved ineffective, leading to disease progression and death. To our best knowledge, this is the first report on the combined use of immune checkpoint inhibitors and radiotherapy as the initial treatment for primary malignant melanoma of the cervix. In advanced cases, initial treatment may result in primary lesion reduction and symptom control.

Source: Current Problems in Cancer Case Reports

DOI: 10.1016/j.cpccr.2025.100396